Just published 🎉: Self-Injection Device Manufacturing in a Dynamic World by Philipp Richard of Ypsomed is now live in the July edition of ONdrugDelivery. The in-depth piece traces the industrial evolution of self-injection devices, from early reusable pens mostly designed for insulin, to today’s wide range of platform products, and offers a detailed look at how flexible manufacturing is key to meeting today’s evolving and ambitious demands. A look at where the field has been—and where it is going 👀. Read the full article below 👇. ONdrugDelivery #ypsomed #OnDrugDelivery #SelfInjection #manufacturing #medtech
Ypsomed AG
Herstellung medizinischer Geräte
Making selfcare simpler and easier.
Info
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company celebrated its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries and distribution partners. Ypsomed has over 2 800 employees worldwide.
- Website
-
https://xmrrwallet.com/cmx.pwww.ypsomed.com/en/company/ypsostories.html
Externer Link zu Ypsomed AG
- Branche
- Herstellung medizinischer Geräte
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Burgdorf
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2003
- Spezialgebiete
- diabetes care, manufacturer, injection systems, selfcare solutions, blood glucose monitoring systems, infusion systems, insulin pumps und digital health
Orte
-
Primär
Brunnmattstrasse 6
Burgdorf, 3401, CH
-
Weissensteinstrasse 26
Solothurn, 4503, CH
Beschäftigte von Ypsomed AG
-
Simon Michel
CEO and Member of the Board at Ypsomed Group and Member of the Swiss National Council
-
Kristen Garland, MAN, RD, CDE
-
Carlos Reboll Romero
General Manager | Sustainable Growth and Expansion | New Market Access | Product Commercialisation | Investment in People | Experience in Multiple…
-
Frederic Richard
Ypsomed Diabetes Care Business Development Director
Updates
-
In the City of Pearls, we are showcasing value that lasts 🤩. Join us at the PDA India Chapter Meeting in Hyderabad (30 Jul–1 Aug) to discuss GLP-1, and how we are rethinking reusables with our 750 μL versions of YpsoPen and ServoPen, and driving access with YpsoFlow, our new spring-driven, pre-filled pen. Let us talk options. See you at table no. 5 💬! #pda #hyderabad #DrugDelivery #ypsomed #India
-
We were honored with the Gold Award in the Drug Delivery Innovation category at the CPHI China Pharma Awards 2025 🏆! Our pre-filled, ready-to-use YpsoDose patch injector platform impressed with its innovative technology for automated drug delivery of high-volume drugs 💉. The jury particularly praised the combination of technological excellence, patient comfort, and manufacturing quality 🤝. #ypsomed #DrugDelivery #cphichina #pharmatech
-
As part of the "Erlebnistage Beruf" event 🚀, we welcomed numerous interested school pupils 👩🎓👨🎓 from the canton of Solothurn to our offices 🏢. Exciting insights into the world of medical technology 💉 gave the young people an opportunity to experience what it means to work at Ypsomed on solutions for the healthcare of tomorrow 💡🤝🌍.
-
-
Last week was a time for celebration 🎉 – and rightly so: 17 of our apprentices in Switzerland successfully completed their apprenticeship at Ypsomed 🎓👏. Congratulations to all of you 🎊 You can be really proud of yourselves 🌟💪! #ypsomed #apprenticeship
-
-
At the Annual General Meeting of Ypsomed Holding AG held on 2 July 2025, the shareholders approved ✅ all proposals put forward by the Board of Directors. Marie-Pierre Zerr was newly elected to the Board of Directors. Gilbert Achermann, Paul Fonteyne, Dr. Martin Münchbach, and Simon Michel were re-elected as Members of the Board, and Gilbert Achermann was confirmed as Chairman of the Board. Read more about the Annual General Meeting 👉 https://xmrrwallet.com/cmx.plnkd.in/d-qx3AGK
-
The Annual General Meeting of Ypsomed AG is taking place today in Burgdorf 📍. The company's Chairman of the Board, Gilbert Achermann, and CEO, Simon Michel, shared great news with shareholders: The injection business is flourishing 💉, and the company is expanding to meet the growing global demand for medical devices for self-care 🌍. Exciting times ahead for innovation and impact 📈. #ypsomed #AnnualGeneralMeeting
-
-
A new chapter in the treatment of obesity begins with the approval of the world's first dual GCG/GLP-1 receptor agonist drug delivered using an Ypsomed autoinjector in China ✨. Innovent Biologics, Inc. (XHKG: 1801), a leading Chinese biopharmaceutical company, has received approval ✅ from the Chinese National Medical Products Administration (NMPA) for Mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of people with obesity, which is now launching in an YpsoMate 1.0 autoinjector variant 🚀. #ypsomed #autoinjector #china #obesity
-
Our polymechanics EFZ are among the eight best apprentices in Switzerland 💪 and have qualified to participate in SwissSkills from 17 to 21 September in Bern 🚀. #ypsomed #apprenticeship #SwissSkills #SwissMadeExcellence
-
On 26 June 2025, Ypsomed opened its first dedicated production site in China with a festive ceremony 🎉. The new facility, located in Changzhou’s high-tech industrial park near Shanghai, was completed in just 14 months and marks a further milestone in the company’s global growth strategy 🌍📈. Around 200 guests from business, politics, and healthcare attended the event. #ypsomed #production #china Read more about our new production site 👉 https://xmrrwallet.com/cmx.plnkd.in/dy-5JSRm